2021-Dec-15 The Landmark FDA Case
The Landmark FDA Case — When Regulatory Uncertainty and Ambiguity Creates an Imminent Hazard
How is the widespread uncertainty and ambiguity over the FDA’s official policy on RF/EMF safety standards being used as a cudgel against the public? Why are the American people being asked to pay $ billions in uncompensated harms from RF/EMF exposure each year, while uber-powerful wireless companies are allowed to escape legal liability and avoid the costs of innovating safe, secure, energy efficient, and climate change friendly technologies? (Public Pays Principle).
A BBILAN panel of leading legal experts will discuss this landmark case whose positive outcome can guide a critical national infrastructure policy that accelerates innovation, protects public health and the environment, and secures for the public a reasonable balance of wireless and wired broadband technologies.
Panelists
Host: Doug Wood, Founder Americans for Responsible Technology: “What is a Responsible Public Policy for RF/EMF Emitting Devices and Human/Environment Exposure?”
Dr. David Carpenter, MD, Director, Institute for Health and the Environment: “Why Does the FDA Continue to Deny the Effects of RF Radiation?”
Julian Gresser, Of Counsel, Swankin & Turner, Co-Founder BroadBand International Legal Action Network (BBILAN): “The Public Pays Principle in Historic and Comparative Perspective”
James S. Turner, Co-Founder, Swankin & Turner: “The FDA Case and the Protection of the Consumer”
Joseph M. Sandri, Co-Founder, The BALANCE GROUP, President National Spectrum Management Association: “Why Effective Protocols and Instruments to Measure Biological Interference Are Decisive?”
References:
Julian Gresser, Koichiro Fujikura, Akio Morishima, Environmental Law in Japan (MIT Press 1981)